Introduction
A biomarker is a characteristic that can be measured and evaluated as an indicator of normal biological processes,
pathological processes, or pharmacological responses to therapeutic interventions. It can explore the pathogenesis
at the molecular level, but also has unique advantages in accurately and sensitively evaluating early and low-level
damage, which can provide early warning and provide clinicians with a basis for auxiliary diagnosis to a large
extent. As a terminal substitute, biomarkers are helpful for the research and development of target drugs.
Interestingly, peptides are ideal biomarker candidates due to their multiple involvement in biological systems,
which can migrate between various parts of the organism, so many pathogenic processes can be reflected by the
characteristics and pathological changes of the polypeptide composition in different body fluids, and the changes in
the abundance of polypeptides related to various diseases can be detected.
Fig. 1.
Overview of the workflow of MS-based proteomics/peptidomics for biomarker discovery. (Wei X, et al., 2009)
Our Services
The discovery of biomarkers can help greatly facilitate the interpretation of clinical trial results.
Creative Proteomics develops and validates biomarker assays according to FDA/EMA guidelines to
minimize technical variability and ensure maximum reproducibility. Thanks to our high-sensitivity detection mass
spectrometry, we provide high-quality peptide biomarker identification services to customers around the world.
Here, our lab technicians offer two common modes of peptide biomarker development: pattern recognition and
single/polybiomarker assays.
- Pattern recognition method: The final information can be obtained only by relying on the high specificity and
sensitivity of MS, without obtaining the identity information of candidate biomarkers.
- Single/polybiomarker assays: This method is more practical and reliable than pattern recognition because peptide
differences in polypeptide expression levels can be verified from collected biological samples from different
sourcess. This analytical method can simultaneously reveal the concentration of analyte molecules with very high
specificity, thanks to the precise macromolecular mass and sequencing capability.
Creative Proteomics have developed a complete workflow for mass spectrometry-based peptidomic
biomarker discovery.
- Sample preparation.
- Separation of protein/peptide samples.
- Identification of proteins/peptides by MS or tandem MS.
- Data processing for bioinformatics tools.
- Validation of results by alternative techniques.
Our peptide biomarker identification service performs two steps simultaneously: identifying the peptides present in a
sample (qualitative) and determining the corresponding concentrations (quantitative). Our expert team screens the
best candidate peptides for customers by combining the two. Throughout the analysis process, mass spectrometry
technology with high resolution, high sensitivity, high throughput and quantitative functions is combined with
liquid chromatography (such as UPLC and nano-LC) to provide the most accurate analysis results.
Our peptide biomarker identification service offers the following tests according to validated guidelines, including
but not limited to.
- Standard Curve
- Accuracy and Precision
- Stable
- Linearity
- Parallelism
- Selectivity and Specificity
- Reproducibility
Advantages of Our Identification of Peptide Biomarkers Service
- Solve problems with expertise and creativity.
- Responsive project management.
- Rich experience in screening peptide drugs.
- Peptide expertise in a wide range of therapeutic disease areas.
- Customized service.
Creative Proteomics is a trusted provider of proteomics analysis services. Thanks to our outstanding
scientists and powerful mass spectrometry platform, we offer comprehensive and high-quality identification of
peptide biomarkers service for global customers. If you have any questions or specific requirements, please feel
free to contact us. We will fulfill your goal.
References
- Wei X, Li L J. (2009). Mass spectrometry-based proteomics and peptidomics for biomarker discovery in
neurodegenerative diseases. Int J Clin Exp Pathol. 2(2):132-148.
